Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week
Nuvation Bio Inc shares slid about 4.7% to $8.05 Friday afternoon, after earlier hitting a session low of $8.05.
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens
Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded.
Company hubNASDAQ:NUVB
Nuvation Bio (NUVB) Stock News & Analysis
Follow the latest Nuvation Bio (NUVB) company news, earnings coverage and investor analysis from TechStock².
Save this hub to your TS2 Signalbook account.
- Latest update
- Articles in this hub
- 4
- Last 30 days
- 0
What investors are watching
- Earnings, guidance and financial performance
- Valuation, trading activity and market sentiment
- Strategy, catalysts and company-specific risks
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade
Shares of Nuvation Bio Inc fell about 6.8% to $8.35 in afternoon trading on Friday, after opening at $8.97 and swinging between $9.13 and $8.30. About 3.3 million shares had changed hands.
Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025
Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™, and a wave of bullish analyst upgrades that continue to roll in today. Seeking Alpha+2Trefis+2
TechStock² Updates
